Palak Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.13 M
- Company Age 30 Year, 6 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 M
- Revenue Growth 3.12%
- Profit Growth -41.96%
- Ebitda 243.25%
- Net Worth 83.61%
- Total Assets 0.62%
About Palak Pharmaceuticals
Palak Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 February 1995 and has a history of 30 years. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.13 M.
The company currently has active open charges totaling ₹1.20 M.
Surendra Singh and Jaswinder Kaur serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231UP1995PTC017564
- Company No.
017564
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Palak Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaswinder Kaur  | Managing Director | 15-May-2006 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Surendra Singh | Director | 15-Feb-1995 | Current |
Financial Performance of Palak Pharmaceuticals.
Palak Pharmaceuticals Private Limited, for the financial year ended 2018, experienced modest growth in revenue, with a 3.12% increase. The company also saw a substantial fall in profitability, with a 41.96% decrease in profit. The company's net worth Soared by an impressive increase of 83.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Palak Pharmaceuticals?
In 2018, Palak Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
H.R.G.M. Formulations Private LimitedSurendra Singh is a mutual person
Charges (Loans)
₹1.20 M
₹0
Charges Breakdown by Lending Institutions
- U.C.O. Bank : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jan 2004 | U.C.O. Bank | ₹1.20 M | Open |
How Many Employees Work at Palak Pharmaceuticals?
Unlock and access historical data on people associated with Palak Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Palak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Palak Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.